
Opinion|Videos|May 1, 2026
Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic
This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Episodes in this series

This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Latest CME
Trending on Urology Times
1
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
2
FDA greenlights phase 1 study of UGN-501 for NMIBC
3
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
4
Urocross shows sustained benefit through 24 months post-removal
5















